SYNE1 and neoplasm: We reasoned that the use of p700 to target CPG2 or other enzymes to tumour sites, rather than antibodies, could overcome some of the issues associated with these ADEPT trials, by potentially reducing immunogenicity, decreasing clearance times and decreasing potential drug resistance due to the ability of p700 to target multiple receptors [11].